Tectonic Therapeutic (TECX) Stock: Buy, Sell, or Hold?
TECX - Tectonic Therapeutic, Inc. Common Stock
$21.09
-0.75 (-3.43%)
▼
5d:
-0.99%
30d:
-15.57%
90d:
-30.56%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When TECX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TECX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TECX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TECX is currently trading at $21.09, which is considered oversold relative to its 30-day fair value range of $21.28 to $26.20.
Technical Outlook: Technically, TECX is in a downtrend. Immediate support is located at $20.45, while resistance sits at $23.61. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: TECX scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (12th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $71.00 (+236.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TECX is in a downtrend. Immediate support is located at $20.45, while resistance sits at $23.61. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: TECX scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (12th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $71.00 (+236.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$21.28 -
$26.20
Company Quality Score
46/100
(HOLD)
Options IV Signal
12th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
91.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 12th percentile)
- BULLISH: Strong technical setup (61/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 236.7% below Wall St target ($71.00)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$21.28 -
$26.20
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.68
(12.7%)
Support & Resistance Levels
Support Level
$20.45
Resistance Level
$23.61
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.43
Wall Street Target
$71.00
(+236.7%)
Share & Embed Analysis
Last updated: October 22, 2026 7:02 PM ET
Data refreshes hourly during market hours. Next update: 8:02 PM
Data refreshes hourly during market hours. Next update: 8:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TECX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 56 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 49 HOLD |
|
TRVI
Trevi Therapeutics Inc |
STRONG BUY
11 analysts |
$28 | 69 BUY |
